TY - JOUR
T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations
AU - Nast, A.
AU - Smith, C.
AU - Spuls, P. I.
AU - Avila Valle, G.
AU - Bata-Csörgö, Z.
AU - Boonen, H.
AU - de Jong, E.
AU - Garcia-Doval, I.
AU - Gisondi, P.
AU - Kaur-Knudsen, D.
AU - Mahil, S.
AU - Mälkönen, T.
AU - Maul, J. T.
AU - Mburu, S.
AU - Mrowietz, U.
AU - Reich, K.
AU - Remenyik, E.
AU - Rønholt, K. M.
AU - Sator, P. G.
AU - Schmitt-Egenolf, M.
AU - Sikora, M.
AU - Strömer, K.
AU - Sundnes, O.
AU - Trigos, D.
AU - van der Kraaij, G.
AU - Yawalkar, N.
AU - Dressler, C.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
UR - http://www.scopus.com/inward/record.url?scp=85097922665&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jdv.16915
DO - https://doi.org/10.1111/jdv.16915
M3 - Article
C2 - 33349983
SN - 0926-9959
VL - 34
SP - 2461
EP - 2498
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 11
ER -